EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3‐YEAR FOLLOW‐UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | Publicación